As Parkinson's disease progresses, more invasive therapies are used that require brain surgery, for example. When these no longer deliver the desired results, physicians often conclude that treatment options are exhausted. A study led by researchers at the Technical University of Munich (TUM) now shows that such patients can still benefit from a change in treatment. So far, however, this option has only been used very rarely.
The penetration of viruses into cells can now be tracked with unprecedented accuracy thanks to Würzburg researchers and their innovative design for pseudoviruses.
In the immune system's fight against cancer and infections, the T cells often lose their power. The team of Würzburg immunologist Martin Vaeth has found a possible explanation for this phenomenon.
It all began with basic research: While conducting laboratory experiments, a team at the Technical University of Munich (TUM) came across an active agent against multidrug-resistant bacteria with a fundamental difference to antibiotics developed to date. The researchers have since established a start-up to develop a new drug based on this agent. The entrepreneurs have now been nominated for Science Breakthrough of the Year in the Science Start-Up category at the international Falling Walls summit.
Sharks have existed for millions of years, rarely develop cancer, and react sensitively to ecological changes. An international study led by Würzburg scientists shows that one explanation lies in the fish's genes.
Snakebites cause around 100,000 deaths worldwide every year. Researchers at the Technical University of Munich (TUM) have investigated how the toxin emerged between 50 and 120 million years ago through the modification of a gene that also occurs in mammals and other reptiles. The results could help with the development of better snakebite treatments and lead to new knowledge for the treatment of illnesses such as type 2 diabetes and hypertension.
New vaccine technology could protect from future Coronaviruses and variants
The project BioMagnetix aims to revolutionize the usage of magnetic nanoparticles in biomedicine. It has now received EXIST start-up funding from the Federal Ministry for Economic Affairs and Climate Action.With a grant of approx. 150,000 Euros, first steps to commercialize the idea can now be taken from the laboratory at the University of Bayreuth towards the market.
- Cells are stimulated by robots measuring just 30 micrometers (µm) - Technological platform developed to produce microrobots - Ion channel mechanisms can be influenced A group of researchers at the Technical University of Munich (TUM) has developed the world’s first microrobot (“microbot”) capable of navigating within groups of cells and stimulating individual cells. Berna Özkale Edelmann, a professor of Nano- and Microrobotics, sees potential for new treatments of human diseases.
Prof. Dr. Markus Jeschek investigates novel biosensors
This website uses cookies and the Matomo web analysis tool. By continuing to browse you agree to our use of cookies. Change your settings here. More information.